Breaking News
January 19, 2019 - Newly identified subset of immune cells may be key to fighting chronic inflammation
January 19, 2019 - New immune response regulators discovered
January 18, 2019 - Poor blood oxygenation during sleep predicts chance of heart-related death
January 18, 2019 - First international consensus on the diagnosis and management of fibromuscular dysplasia
January 18, 2019 - Rapid resistance gene sequencing technology can hasten identification of antibiotic-resistant bacteria
January 18, 2019 - Researchers develop artificial enzymatic pathway for synthesizing isoprenoids in E. coli
January 18, 2019 - Scientists advise caution in immunotherapy research
January 18, 2019 - How children across the world develop language
January 18, 2019 - Columbia Medical Student Receives McDonogh Scholarship
January 18, 2019 - Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
January 18, 2019 - Plant based diet could be the best option for the planet says commission
January 18, 2019 - New conservation practice could reduce nitrogen from agricultural drainage, study shows
January 18, 2019 - UIC researchers receive $1.7 million NCI grant to study Southeast Asian fruit
January 18, 2019 - New study determines the fate of DNA derived from genetically modified food
January 18, 2019 - Scientists develop new gene therapy that prevents axon destruction in mice
January 18, 2019 - Study finds critically low HPV vaccination rates among younger adolescents in the U.S.
January 18, 2019 - Brain cells involved in memory play key role in reducing future eating behavior
January 18, 2019 - Risk for Conversion of MS Varies With Different Therapies
January 18, 2019 - Investigational cream may help patients with inflammatory skin disease
January 18, 2019 - Medical school news office receives six writing awards | News Center
January 18, 2019 - County By County, Researchers Link Opioid Deaths To Drugmakers’ Marketing
January 18, 2019 - Research reveals risk for developing more than one mental health disorder
January 18, 2019 - Scientists discover a dramatic pattern of bone growth in female mice
January 18, 2019 - Study finds link between lengthy periods of undisturbed maternal sleep and stillbirths
January 18, 2019 - New nuclear medicine method could improve detection of primary and metastatic melanoma
January 18, 2019 - Combination therapy shows high efficacy in treating people with leishmaniasis and HIV
January 18, 2019 - Health Tip: Don’t Ignore Changes in Skin Color
January 18, 2019 - Dietary Recommendations for Healthy Children
January 18, 2019 - Eliminating the latent reservoir of HIV
January 18, 2019 - Pain From The Government Shutdown Spreads. This Time It’s Food Stamps
January 18, 2019 - Newly discovered regulatory mechanism helps control fat metabolism
January 18, 2019 - New rapid blood tests could speed up TB diagnosis, save the NHS money
January 18, 2019 - Researchers develop intelligent system for ‘tuning’ powered prosthetic knees
January 18, 2019 - Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma
January 18, 2019 - New research detects mosquito known to transmit malaria for the first time in Ethiopia
January 18, 2019 - Lumex Instruments’ RA-915AM monitor installed at Hg treatment plant in Almadén, Spain
January 18, 2019 - ACCC survey finds multiple threats to growth of cancer programs
January 18, 2019 - Meeting the challenge of engaging men in HIV prevention and treatment
January 18, 2019 - Furloughed Feds’ Health Coverage Intact, But Shutdown Still Complicates Things
January 18, 2019 - Experts discuss various aspects on health risks posed by fumigated containers
January 18, 2019 - Researchers use gene-editing tool CRISPR/Cas9 to limit impact of parasitic diseases
January 18, 2019 - Alpha neurofeedback training could be a means of enhancing learning success
January 18, 2019 - Innovative ‘light’ method demonstrates positive results in fight against malignant tumors
January 18, 2019 - The cytoskeleton of neurons found to play role in Alzheimer’s disease
January 18, 2019 - New resource-based approach to improve HIV care in low- and middle-income countries
January 18, 2019 - Bedfont appoints Dr Jafar Jafari as first member of the Gastrolyzer Medical Advisory Board
January 18, 2019 - New study shows link between secondhand smoke and cardiac arrhythmia
January 18, 2019 - DZIF scientists reveal problems with available diagnostics for Zika and chikungunya virus
January 18, 2019 - Breast cancers more likely to metastasize in young women within 10 years of giving birth
January 18, 2019 - Over 5.6 million Americans exposed to high nitrate levels in drinking water
January 18, 2019 - Blood vessels can now be created perfectly in a petri dish
January 18, 2019 - Study identifies prominent socioeconomic and racial disparities in health behavior in Indiana
January 18, 2019 - Young-Onset Type 2 Diabetes Tied to Increased Hospitalization Risk
January 18, 2019 - For-profit nursing schools associated with lower performance on nurse licensure test
January 18, 2019 - Considering the culture of consent in medicine
January 18, 2019 - Researchers identify comprehensive guidelines for managing severe atopic dermatitis
January 18, 2019 - Analyzing proteins in blister fluid may classify burn severity more accurately
January 18, 2019 - Study finds higher suicide rates among youth who were Medicaid enrollees
January 18, 2019 - Opioid drugs often overprescribed to children for pain relief, say CHOP surgeons
January 18, 2019 - New biodegradable wound dressing material accelerates healing
January 18, 2019 - Life in Space May Take Toll on Spinal Muscles
January 18, 2019 - Bulldogs’ screw tails linked to human genetic disease
January 18, 2019 - Immunotherapy target identified for pediatric cancers
January 18, 2019 - Financial stress may increase heart disease risk in African Americans
January 18, 2019 - Scientists solve another piece of Ebola virus puzzle
January 18, 2019 - New project finds how endocrine disruptors interfere with thyroid functions
January 18, 2019 - Research finds decline in ketone body utilization when coronary circulation is reduced
January 18, 2019 - Let’s map our DNA and save billions each year in health costs
January 18, 2019 - AI demonstrates potential to identify irregular heart rhythms as well as humans
January 17, 2019 - Study shows link between air pollution and increased risk of sleep apnea
January 17, 2019 - Neck-strengthening exercises can protect athletes from concussions
January 17, 2019 - Computer model shows how to better control MRSA outbreaks
January 17, 2019 - Pain is unpleasant, and now scientists have identified the set of responsible neurons
January 17, 2019 - CUIMC Celebrates 2018-2019
January 17, 2019 - Study reveals potential pathway for endothelial cells to avoid apoptosis
January 17, 2019 - Hamilton Storage launches LabElite DeCapper SL to expand LabElite product family
January 17, 2019 - Location of epigenetic changes co-locate with genetic signal causing psychartric disorder
January 17, 2019 - Researchers awarded 6.1 million euros to address female fertility problems
January 17, 2019 - Counseling appointments fail to reduce weight gain during pregnancy, shows study
January 17, 2019 - Contraceptive patch that could provide 6 months of contraception within seconds
Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

image_pdfDownload PDFimage_print

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression.

Studies have shown reduced recurrence and breast cancer mortality with zoledronic acid plus hormonal therapy in HR+ breast cancer in postmenopausal women, but the benefit in premenopausal women was previously less clear. Zoledronic acid is a bisphosphonate that reduces the rate of bone turnover; it is licensed to treat osteopororosis and to reduce bone damage in advanced cancers involving bone and hypercalcemia in cancer. Unlike tamoxifen, which blocks estradiol binding to the estrogen receptor, letrozole is an aromatase inhibitor that profoundly suppresses estradiol levels but has not previously been evaluated in premenopausal breast cancer.

The HOBOE-2 (Hormonal BOne Effects-2) phase 3 trial included 1065 patients with estrogen/progesterone receptor positive early breast cancer who had their last period within one year of randomization. They were treated with the gonadotrophin-releasing hormone agonist triptorelin (3.75mg every four weeks) for five years up to the age of 55 to suppress ovarian function and nearly two-thirds (63%) received chemotherapy before randomization.

The patients were randomized to hormonal therapy with tamoxifen (20mg/day) or letrozole (2.5mg/day) or to combination therapy with zoledronic acid (4mg IV every six months) plus letrozole (2.5mg/day) (ZL) for a planned treatment duration of five years. The study was stopped early in May 2018 after a median follow-up of 65 months when the Independent Monitoring Committee recommended sharing the data with the Early Breast Cancer Trialists’ Cooperative Group (EBCTCG) 2018 overview.

Results reported at ESMO 2018 showed there were 32 breast cancer recurrences or second breast or non-breast cancers or deaths in patients treated with ZL, giving a 5-year disease-free survival (DFS) probability of 0.93. There were 58 events in patients treated with tamoxifen and 44 events in the letrozole group, giving 5-year DFS event rates of 0.85 and 0.93, respectively (p=0.008).

Disease-free survival was significantly improved in patients randomized to zoledronic acid plus letrozole compared to those treated with tamoxifen, with an absolute advantage of 8% in 5-year DFS. The risk of breast cancer recurrence or non-cancer death was nearly halved in patients treated with ZL compared to those treated with T (hazard ratio [HR] 0.52, 95% confidence interval 0.34-0.80, p=0.003).

The improvement in DFS with ZL compared to tamoxifen was seen in all subgroups of patients apart from the small subgroup of women with tumors overexpressing HER2 who showed greater benefit with tamoxifen (interaction p=0.002).

There was no statistically significant difference in DFS comparing letrozole with tamoxifen (HR 0.72, 95% CI 0.48-1.07, p=0.06) or comparing ZL with letrozole alone (HR 0.70, 95% CI 0.44-1.12, p=0.22).

As expected, side-effects were more frequent in patients treated with ZL, with 9% of patients experiencing grade 3-4 toxicity compared to 4% of those treated with T and 7% of those treated with L. Nearly one in five (17%) patients treated with ZL stopped treatment before 5 years due to toxicity or refusal, compared to 7% of those on T and 7% of those on L. Among the most feared side-effects associated with the study drugs, there were four cases of jaw osteonecrosis in the ZL arm.

“HOBOE-2 strongly supports the hypothesis that combination treatment with an aromatase inhibitor and bisphosphonate plus triptorelin may improve prognosis in premenopausal patients with HR-positive breast cancer,” said lead author Prof. Francesco Perrone, Director of the Clinical Trials Unit at the Istituto Nazionale Tumori, Naples, Italy.

Perrone continued: “We had previously shown that, in combination with triptorelin, letrozole suppresses estradiol levels much more than tamoxifen in premenopausal patients. And we know that suppressing estradiol levels means cutting the fuel to endocrine-dependent breast cancer.”

Considering zoledronic acid, Perrone said: “Our hypothesis is that the drug modifies the bone microenvironment that is the niche where breast cancer micrometastases remain in a state of dormancy, potentially for many years. Microenvironment modifications may be lethal for isolated cancer cells, reducing the risk of distant metastases over time.” He explained: “The two mechanisms are partially independent and, therefore, may sum up to give an additive benefit.”

Reviewing the potential impact on clinical practice, Perrone suggested: “If the size of the benefit we saw is confirmed with longer follow-up, ZL treatment might turn out to be a highly cost-effective treatment for premenopausal HR+ breast cancer.” He noted that zoledronic acid and letrozole are both very cheap drugs, so could be used widely.

Commenting on the study for ESMO, Robert Coleman, Emeritus Professor of Medical Oncology, University of Sheffield, UK, said: “The findings add to existing information to support the use of more intensive treatment with an aromatase inhibitor and bisphosphonate in women at high risk for recurrence, either by virtue of node involvement or high-grade or large tumors.” He noted: “Both treatments add toxicity over and above tamoxifen and so are best limited to women at intermediate to high risk where the risk-benefits are likely to be acceptable.”

Coleman cautioned that the study was underpowered, with insufficient events for statistical confidence in the results. He added: “This study is not definitive but adds to the information on these two treatment approaches and will contribute to the ongoing EBCTCG meta-analyses.” He considered there were unlikely to be further trials with aromatase inhibitors and bisphosphonates as the focus is now on adding other targeted treatments.

Source:

https://www.esmo.org/Press-Office/Press-Releases/HOBOE-breast-cancer-Triptorelin-Perrone

Tagged with:

About author

Related Articles